Ironwood Pharmaceuticals
IRWD
261 hedge funds and large institutions have $1.5B invested in Ironwood Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 84 increasing their positions, 85 reducing their positions, and 43 closing their positions.
1,107% more call options, than puts
Call options by funds: $241M | Put options by funds: $20M
26% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 43
4% more funds holding
Funds holding: 251 → 261 (+10)
3.07% more ownership
Funds ownership: 107.05% → 110.12% (+3.1%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 85
22% less capital invested
Capital invested by funds: $1.91B → $1.5B (-$412M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$87.4M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
+$42.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$42.3M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$31.3M |
| 5 |
State Street
Boston,
Massachusetts
|
+$28.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$65.7M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$49.7M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$35.7M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$25.4M |
| 5 |
BlackRock
New York
|
-$22.1M |
IRWD Hedge Fund Activity: Q1 2024 in Review
261 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q1 2024, worth a combined $1.5B — down 22% from $1.91B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new IRWD positions and 43 closed out — a net gain of 11 holders — while 84 added to existing stakes and 85 trimmed.
The largest buyer was Pacer Advisors, opening a new position worth an estimated $87.4M. The largest seller was Credit Suisse, cutting an estimated $65.7M.
- 261 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q1 2024, up from 251 in Q4 2023.
- Funds reported $1.5B of Ironwood Pharmaceuticals stock for Q1 2024, down 22% quarter-over-quarter.
- 54 funds opened new Ironwood Pharmaceuticals positions in Q1 2024 and 43 closed out, a net change of +11 holders.
- The largest Ironwood Pharmaceuticals buyer in Q1 2024 was Pacer Advisors, an estimated $87.4M added.
- The largest Ironwood Pharmaceuticals seller in Q1 2024 was Credit Suisse, an estimated $65.7M sold.
Based on aggregated 13F filings for Q1 2024.